Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities
© 2023. The Author(s)..
High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4+ and CD8+ T cells. In First Nations participants, RBD IgG antibody titers were correlated with body mass index and negatively correlated with age. Reduced RBD antibodies, spike-specific B cells and follicular helper T cells were found in vaccinated participants with chronic conditions (diabetes, renal disease) and were strongly associated with altered glycosylation of IgG and increased interleukin-18 levels in the plasma. These immune perturbations were also found in non-Indigenous people with comorbidities, indicating that they were related to comorbidities rather than ethnicity. However, our study is of a great importance to First Nations peoples who have disproportionate rates of chronic comorbidities and provides evidence of robust immune responses after COVID-19 vaccination in Indigenous people.
| Errataetall: |
CommentIn: Nat Immunol. 2023 Jun;24(6):889-890. - PMID 37248418 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Nature immunology - 24(2023), 6 vom: 29. Juni, Seite 966-978 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 02.06.2023 Date Revised 21.08.2023 published: Print-Electronic CommentIn: Nat Immunol. 2023 Jun;24(6):889-890. - PMID 37248418 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41590-023-01508-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357505948 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357505948 | ||
| 003 | DE-627 | ||
| 005 | 20231226072735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41590-023-01508-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357505948 | ||
| 035 | |a (NLM)37248417 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Wuji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2023 | ||
| 500 | |a Date Revised 21.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Immunol. 2023 Jun;24(6):889-890. - PMID 37248418 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4+ and CD8+ T cells. In First Nations participants, RBD IgG antibody titers were correlated with body mass index and negatively correlated with age. Reduced RBD antibodies, spike-specific B cells and follicular helper T cells were found in vaccinated participants with chronic conditions (diabetes, renal disease) and were strongly associated with altered glycosylation of IgG and increased interleukin-18 levels in the plasma. These immune perturbations were also found in non-Indigenous people with comorbidities, indicating that they were related to comorbidities rather than ethnicity. However, our study is of a great importance to First Nations peoples who have disproportionate rates of chronic comorbidities and provides evidence of robust immune responses after COVID-19 vaccination in Indigenous people | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Kedzierski, Lukasz |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Brendon Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mayo, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Lonzi, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Rigas, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Bianca F |e verfasserin |4 aut | |
| 700 | 1 | |a McQuilten, Hayley A |e verfasserin |4 aut | |
| 700 | 1 | |a Rowntree, Louise C |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Lilith F |e verfasserin |4 aut | |
| 700 | 1 | |a Purcell, Ruth A |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Hyon-Xhi |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Chaurasia, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Mordant, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pogorelyy, Mikhail V |e verfasserin |4 aut | |
| 700 | 1 | |a Minervina, Anastasia A |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, Jeremy Chase |e verfasserin |4 aut | |
| 700 | 1 | |a Perkins, Griffith B |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Gras, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Clemens, E Bridie |e verfasserin |4 aut | |
| 700 | 1 | |a Juno, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Audsley, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Khoury, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, Natasha E |e verfasserin |4 aut | |
| 700 | 1 | |a Thevarajan, Irani |e verfasserin |4 aut | |
| 700 | 1 | |a Subbarao, Kanta |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Allen C |e verfasserin |4 aut | |
| 700 | 1 | |a Davenport, Miles P |e verfasserin |4 aut | |
| 700 | 1 | |a Grubor-Bauk, Branka |e verfasserin |4 aut | |
| 700 | 1 | |a Coates, P Toby |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Wheatley, Adam K |e verfasserin |4 aut | |
| 700 | 1 | |a Kent, Stephen J |e verfasserin |4 aut | |
| 700 | 1 | |a Rossjohn, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Amy W |e verfasserin |4 aut | |
| 700 | 1 | |a Boffa, John |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Lynar, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Thi H O |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Kedzierska, Katherine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature immunology |d 2000 |g 24(2023), 6 vom: 29. Juni, Seite 966-978 |w (DE-627)NLM10805523X |x 1529-2916 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:6 |g day:29 |g month:06 |g pages:966-978 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41590-023-01508-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 6 |b 29 |c 06 |h 966-978 | ||